Analgesic effect of neoadjuvant denosumab in Grade III giant cell tumor of bone.

Authors

  • Badaruddin Sahito Dow University of Health Sciences/Civil Hospital Karachi.
  • Sana Shahid Dow University of Health Sciences/Civil Hospital Karachi.
  • Arsia Hanif Dow University of Health Sciences/Civil Hospital Karachi.
  • Nasim Munshi Ziauddin Hospital, Karachi.
  • Muhammad Soughat Katto Dow University of Health Sciences/Civil Hospital Karachi.
  • Azam Kamboh Dow University of Health Sciences/Civil Hospital Karachi.
  • Sheikh Muhammad Ebad Ali Aga Khan University Hospital, Karachi.

DOI:

https://doi.org/10.29309/TPMJ/2022.29.05.6890

Abstract

Objective: To assess the pain relief after denosumab use in grade III giant cell tumor of bone (GCT-B). Study Design: Retrospective Cohort study. Setting: Department of Orthopedic Surgery Dow University of Health Sciences / Dr Ruth KM Pfau Civil Hospital Karachi. Period: 2018 May to 2020 June. Material & Methods: Total 27 patients were included in the study with diagnosis of grade III GCT-B. Patients with Stage I & II excluded from study. Results: After the first dose of Denosumab, 24 (88.9%) patients reported no pain relief while the other 3 (11.1%) patients had mild pain. A second dose of Denosumab was given to these patients. After the second dose, 3 (11.1%) patients scored mild pain and 24 patients had a score of ≥4 on VAS. The pain severity reduced significantly after administration of 2nd dose of Denosumab (p=0.019). Pain severity was remeasured after the third dose of Denosumab where they had VAS of 0 to 6, with inconsistent use of simple analgesics. The pain severity reduced significantly after administration of 3rd dose of Denosumab (p=0.001). Conclusion: We conclude that denosumab have excellent analgesic effect in grade III giant cell tumor of bone. We recommend the use denosumab in perioperative therapy for grade III GCT-B bone and we found analgesic effect as additional one. It may gain some time for patient specially in developing nations where oncology surgery centers are limited. It also reduces the use of NSAIDS during window period of definitive surgery.

Author Biographies

Badaruddin Sahito, Dow University of Health Sciences/Civil Hospital Karachi.

MBBS, FCPS, Associate Professor Orthopaedic Surgery, 

Sana Shahid, Dow University of Health Sciences/Civil Hospital Karachi.

MBBS, Resident General Surgery, 

Arsia Hanif, Dow University of Health Sciences/Civil Hospital Karachi.

MBBS, Resident General Surgery, 

Nasim Munshi, Ziauddin Hospital, Karachi.

MBBS, FCPS, Assistant Professor Orthopaedic Surgery, 

Muhammad Soughat Katto, Dow University of Health Sciences/Civil Hospital Karachi.

MBBS, FCPS, Assistant Professor Orthopaedic Surgery, 

Azam Kamboh, Dow University of Health Sciences/Civil Hospital Karachi.

MBBS, Resident Orthopaedic Surgery, 

Sheikh Muhammad Ebad Ali, Aga Khan University Hospital, Karachi.

MBBS, Research Associate Emergency Medicine, 

Downloads

Published

2022-04-30